Decreasing Poly(ADP-Ribose) Polymerase Activity Restores ΔF508 CFTR Trafficking by Suzana M. Anjos et al.
ORIGINAL RESEARCH ARTICLE
published: 12 September 2012
doi: 10.3389/fphar.2012.00165
Decreasing poly(ADP-ribose) polymerase activity restores
∆F508 CFTR trafficking
Suzana M. Anjos1*, Renaud Robert 2, DanielWaller 1, Dong Lei Zhang1, Haouaria Balghi 2,
Heidi M. Sampson1, Fabiana Ciciriello1, Pierre Lesimple2, GraemeW. Carlile1, Julie Goepp2, Jie Liao2,
Pasquale Ferraro3, Romeo Phillipe4, Françoise Dantzer 5, JohnW. Hanrahan2 and DavidY.Thomas1
1 Cystic Fibrosis Translational Research Center, Department of Biochemistry, McGill University, Montreal, QC, Canada
2 Cystic Fibrosis Translational Research Center, Department of Physiology, Montreal QC, Canada
3 Division of Thoracic Surgery, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada
4 Department of Pathology, Montreal Heart Institute, Université de Montréal, Montréal, QC, Canada
5 University of Strasbourg, Illkirch, France
Edited by:
Frederic Becq, University of Poitiers,
France
Reviewed by:
Giulio Cabrini, University Hospital of
Verona, Italy
Jean-Michel Sallenave, Université
Paris 7 Denis Diderot/Institut Pasteur,
France
*Correspondence:
Suzana M. Anjos, Cystic Fibrosis
Translational Research Center,
Department of Biochemistry, McGill
University, 3655 Promenade Sir
William Osler, Room 902, Montreal,
QC, Canada H3G 1Y6.
e-mail: suzana.anjos@mail.mcgill.ca
Most cystic fibrosis is caused by mutations in CFTR that prevent its trafficking from the ER
to the plasma membrane and is associated with exaggerated inflammation, altered metab-
olism, and diminished responses to oxidative stress. PARP-1 is activated by oxidative stress
and causes energy depletion and cell dysfunction. Inhibition of this enzyme protects against
excessive inflammation and recent studies have also implicated it in intracellular protein
trafficking. We hypothesized that PARP-1 activity is altered in CF and affects trafficking and
function of the most common CF mutant ∆F508 CFTR. Indeed, PARP-1 activity was 2.9-
fold higher in CF (∆F508/∆F508) human bronchial epithelial primary cells than in non-CF
cells, and similar results were obtained by comparing CF vs. non-CF bronchial epithelial cell
lines (2.5-fold higher in CFBE41o− vs. 16HBE14o−, P <0.002). A PARP-1 inhibitor (ABT-
888, Veliparib) partially restored CFTR channel activity in CFBE41o− cells overexpressing
∆F508 CFTR. Similarly, reducing PARP-1 activity by 85% in ileum from transgenic CF mice
(Cftrtm1 Eur ) partially rescued ∆F508 CFTR activity to 7% of wild type mouse levels, and
similar correction (7.8%) was observed in vivo by measuring salivary secretion. Inhibiting
PARP-1 with ABT-888 or siRNA partially restored ∆F508 CFTR trafficking in cell lines, and
most ∆F508 CFTR was complex glycosylated when heterologously expressed in PARP-
1−/− mouse embryonic fibroblasts. Finally, levels of the mature glycoform of CFTR were
reduced by peroxynitrite, a strong activator of PARP-1. These results demonstrate that
PARP-1 activity is increased in CF, and identify a novel pathway that could be targeted by
proteostatic correctors of CFTR trafficking.
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INTRODUCTION
Cystic fibrosis is the most prevalent inherited disease amongst
Caucasians, afflicting ∼70,000 people worldwide (Riordan et al.,
1989). The symptoms of cystic fibrosis include progressive respira-
tory dysfunction due to persistent and repeated cycles of infection
and inflammation, and are caused by mutations in the cystic fibro-
sis transmembrane conductance regulator (CFTR) gene. CFTR
encodes an ATP-binding cassette (ABC) transporter that func-
tions as a tightly regulated anion channel. Over 1,900 mutations in
CFTR have been identified, the most prevalent being an in-frame
deletion of Phe at the 508 position (∆F508; Bobadilla et al., 2002).
This mutation, which is present on at least one chromosome in
90% of people with CF, causes the mutant protein to be recognized
by the cellular quality control machinery and retained at the ER
where it is then degraded (Cheng et al., 1990).∆F508 also reduces
the open probability of mutant channels that reach the plasma
membrane shortening their half-life at the cell surface (Lukacs
et al., 1994). Although the life expectancy for CF patients has
improved in recent years due to improved antibiotics, pancreatic
enzyme supplements, and therapeutic regimens, there remains no
cure for most people with CF who carry CFTR mutations that
cause defective trafficking.
Cystic fibrosis transmembrane conductance regulator muta-
tions cause a myriad of downstream biological changes, and the
relationship between these changes and the disease phenotype
remains poorly understood. Markers of oxidative stress are ele-
vated in the plasma, presumably due to pulmonary infection
(Brown et al., 1996; Collins et al., 1999). CF patients also dis-
play increased susceptibility to oxidative-induced DNA damage
as measured by urinary excretion of 8-hydroxydeoxyguanosine,
and this sensitivity to oxidants may be an inherent property of
the disease since it appears to be independent of clinical status
(Brown et al., 1995). High intracellular levels of hydrogen perox-
ide and mitochondrial reactive oxygen species (ROS) have been
reported in CFTR-deficient cells (Rottner et al., 2009), and a defi-
ciency in reduced glutathione (GSH) in the respiratory epithelial
lining fluid and plasma has been known for some time (Roum
et al., 1993). Thus several lines of evidence suggest that CF leads
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to redox disturbances, as recently reviewed (Galli et al., 2012).
One mechanism used by cells to protect against oxidative DNA
damage is PolyADP (Ribose) Polymerase-1 (PARP-1), the most
abundant isoform of a family of nuclear enzymes that sense
DNA damage and initiate DNA repair. PARP-1 is activated by cell
stress and plays an important role during tissue injury (Luo and
Kraus, 2005; Pacher and Szabo, 2008). It uses NAD+ to trans-
fer polymers of ADP-ribose to target proteins at the expense
of ATP, a post-translational modification known as poly ADP-
(ribosyl)ation (PARylation). PARP-1 function depends on the
type, duration and strength of the stress stimuli, and on the prolif-
erative and metabolic state of the cell (Luo and Kraus, 2005), and
is intimately tied to nuclear NAD+ metabolism and the broader
cellular metabolic profile (Luo and Kraus, 2005).
Under conditions of cell stress the nuclear enzyme poly(ADP-
ribose) polymerase-1 (PARP-1) becomes hyperactive and depletes
cells of NAD+. This slows glycolysis, reduces electron transport
and ATP formation, and may lead to the upregulation of proin-
flammatory pathways or cell death (Cuzzocrea, 2005; Pacher and
Szabo, 2008). Thus, from a pathophysiological standpoint, PARP
activation could contribute to disease by driving the cell into
an energetic deficit, and also by inducing a state of dysfunc-
tion through activation of proinflammatory pathways (Cuzzocrea,
2005). Both these mechanisms have been implicated in CF. We
hypothesize that the misfolded mutant CFTR is associated with
an increase in PARP activity. Decreasing this activity may restore
some functional correction.
In this study we have investigated a possible role of PARP-1
in the regulation of ∆F508 CFTR trafficking and function in CF
bronchial epithelial cells. The involvement of PARP-1 in oxida-
tive stress, inflammatory responses, and energy maintenance, and
its emerging role as a regulator of intracellular protein trafficking
(Abd Elmageed et al., 2011) suggested that it may be an interesting
potential target for small molecule correctors in Cystic fibrosis.
MATERIALS AND METHODS
REAGENTS
4-Amino-1,8-naphthalimide (4-AN) and N-(6-Oxo-5,6-dihydro
phenanthridin-2-yl)-(N,N-dimethylamino)acetamide hydrochlo-
ride (PJ34) were obtained from Sigma-Aldrich (Oakville Ontario,
Canada). (2-((2R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-
4-carboxamide dihydrochloride; ABT-888) was purchased from
Alexis Biochemicals (Famingdale, NY, USA). VRT-325 was a gen-
erous gift from Dr. Robert Bridges (Rosalind Franklin Univer-
sity of Medicine and Science) and the Cystic Fibrosis Founda-
tion Therapeutics Inc. (CFFT). The monoclonal antibody against
the R domain of CFTR (clone 23C5) was generated by our lab
(Myriam Mirza, Veli-Pekka Määttänen and D. Y. T., unpublished
data). M3A7 monoclonal antibody against CFTR was purchased
from Chemicon (Billerica, MA, USA). α-tubulin was obtained
from Sigma-Aldrich and monoclonal antibody (IgG2a) against
PARP-1 was from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-PAR was obtained from Trevigen (Gaithersburg, MD,
USA). Rabbit anti-hERG antibody was obtained from Calbiochem
(Burlington, Ontario, Canada). Peroxynitrite (tetramethylammo-
nium) was obtained from Alexis Biochemicals and prepared in ice
cold 0.01 M KOH as per the manufacturer’s instructions.
Homozygous ∆508 CFTR mice (Cftrtm1 Eur ; van Doorninck
et al., 1995) and wild type littermates controls were used in the
ex vivo experiments. Breeders and protocols for mouse intestinal
assays were kindly provided by B. J. Scholte, M. Wilke, and H. R.
de Jonge, Erasmus University Medical Center, Rotterdam, NL. The
mice were kept in the animal facility at McGill University and fed
a high protein diet (SRM-A, Hope Farms, Woerden, Netherlands)
modified to contain pork instead of beef. All procedures followed
Canadian Institutes of Health Research (CIHR) regulations and
were approved by the faculty Animal Care Committee of McGill
University.
CELL CULTURE AND TREATMENTS
HEK293 cells were stably transfected with HA tagged hERG G601S
(generous gift of E. Ficker; Wible et al., 2005) and maintained in
standard culture conditions.
Stably transfected BHK cells expressing histidine-tagged (His)
wt-CFTR or∆F508 CFTR were maintained in DMEM-F12 media
supplemented with 5% FBS and 450µM methotrexate. 1% l-
Glutamax. CFBE41o− cell lines transduced with TranzVector
lentivectors containing∆F508 CFTR (CFBE41o-∆F508) and wild
type CFTR (CFBE41o−CFTR) cells were kindly provided by J.
P. Clancy (Bebok et al., 2005) and were maintained in EMEM
(Wisent, St-Bruno, QC, USA) supplemented with 10% FBS and
1% l-Glutamax. For polarized CFBE41o− monolayers (∆F508
and wt-CFTR), cells were cultured under liquid/liquid condi-
tions and polarized at the air/liquid interface. Cells were seeded
at a density of 2.5× 105 cells/cm2 onto 12 mm fibronectin-coated
Snapwell inserts (Corning Incorporated). The apical medium was
removed after 24 h to establish an air-liquid interface (ALI), and
then the cells were cultured for another 6–7 days (Bebok et al.,
2005). CFBE41o− cells were treated with 4-AN (Sigma-Aldrich),
PJ34 (Sigma-Aldrich), or ABT-888 (Alexis Biochemicals) for 24 h
or as shown and at the indicated concentrations. Low temperature
rescue was carried out at 29˚C for 24 h or as indicated. DMSO was
used as a vehicle at a 1:1000 dilution. Primary Human Bronchial
Epithelial cells (HBEs) were isolated from human bronchial tissue
by enzyme digestion and cultured in bronchial epithelial growth
medium (BEGM; Fulcher et al., 2005) on vitrogen-coated plas-
tic flasks (Vitrogen 100, PureCol, Advanced BioMatrix #5005-B).
They were then trypsinized, counted, and cryopreserved or trans-
ferred onto collagen VI-coated snapwell culture inserts (Corning,
catalog no. 3801) in ALI medium (Fulcher et al., 2005) at a density
of 2.5× 105 cells/insert. During the first 4 days, the ALI medium
was changed daily, then apical media was removed and the cells
were grown in an ALI for 22 days before use. For the CF HBE cells,
the isolation and growth media were complemented with specific
antibiotics based on the patient’s microbiology report.
IMMUNOBLOTTING AND DENSITOMETRY
BHK cells overexpressing (His) ∆F508 CFTR and wt-CFTR, and
CFBE41o− cells (overexpressing∆F508 and wt-CFTR) were lysed
in RIPA buffer containing protease inhibitors (Roche, Inc.) and
0.8% deoxycholic acid prepared as described (Robert et al., 2008).
Briefly, 10µg (BHK) and 20µg (CFBE41o−) total protein were
separated using 6% (v/v) SDS-PAGE and transferred onto nitro-
cellulose membranes. Membranes were probed with monoclonal
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anti-CFTR antibody (clone 23C5) at a 1:10 dilution overnight at
4˚C for CFBE41o− lysates or 1:1000 dilution for BHK lysates (clone
M3A7). Membranes were reprobed for PARP1 with monoclonal
antibody against PARP1 at a 1:500 dilution. For immunoblotting
against hERG in the HEK293 cells, polyclonal antibody against
hERG was used overnight at 4˚C at 1:1000 dilution. Membranes
were probed with monoclonal anti-tubulin (Sigma-Aldrich) to
normalize for protein loading. The relative levels of each CFTR
glycoform were estimated by densitometry using the Image J pro-
gram (http://rsb.info.nih.gov/ij/). The relative amount of band B
or band C is calculated as a fraction of tubulin for the respective
lane and reported as a fraction of the total (band C/tub+ band
B/tub). The values reported are expressed as means± SD (n= 3).
Data sets were compared by a Student’s t -test using SigmaPlot
(Systat Software, Inc.).
HALIDE FLUX ASSAY AND VOLTAGE CLAMP STUDIES OF CFBE41o−
CELL MONOLAYERS
Iodide efflux from BHK cells expressing (His) ∆F508 CFTR was
assayed using a robotic liquid handling system (BioRobot 800 Qia-
gen, USA) and Qiagen 4.1 software. Iodide concentration at the
end of each sample period was measured using an iodide-sensitive
electrode (Orion Research, Inc., Boston, MA, USA) and converted
to iodide content released per 1 min interval. Relative iodide efflux
rates were calculated by subtracting the baseline from the peak
iodide flux (in µmol/min). Data were calculated from at least
three independent experiments each with four replicates, and are
reported as±SEM. Short-circuit current (I sc) was measured across
monolayers mounted in modified Ussing chambers. CFBE41o−
cells over expressing ∆F508 CFTR and wt-CFTR (250 000) were
seeded onto 12-mm fibronectin-coated Snapwell inserts (Corn-
ing Incorporated) and the apical medium was removed after 24 h
to establish an ALI. CFBE41o− ∆F508 monolayers were treated
on both sides with Opti-MEM medium (no FBS) and one of the
following compounds: 0.1% DMSO (negative control), 1 nM ABT-
888, 10µM VRT325. Alternatively, CFBE41o−∆F508 cells were
incubated at 29˚C (positive control) for 24 h before being mounted
in chambers and voltage clamped using a VCCMC6 multichannel
current-voltage clamp (Physiologic Instruments, San Diego, CA,
USA). The assay was performed as described previously (Robert
et al., 2008).
PARP1−/− AND PARP1+/+ MOUSE EMBRYONIC FIBROBLASTS
PARP1−/− and PARP1+/+ MEFs were obtained from Françoise
Dantzer (CR1, CNRS, University of Strasbourg, France) and
maintained in DMEM supplemented with FBS (10%) and gen-
tamicin (1%) at 37˚C, 5% CO2. The cells were transfected with
wild type or ∆F508 triple-HA tagged CFTR in pcDNA3.1 plas-
mid using Fugene according to the manufacturer’s guidelines.
Briefly, 2× 105 cells were seeded in a 6-well plate and transfected
when at least 50% confluent using 7µl Fugene: 2µg DNA. For
immunoblotting, 40–50µg of total protein was loaded into each
lane and membranes were probed with monoclonal antibodies
against CFTR and tubulin (see above).
PARP ACTIVITY ASSAYS
Approximately 5× 104/200µl CFBE41o− cells were cultured
in 96 well plates and treated with ABT-888 at the indicated
concentrations for 24 h. Cells were then lysed buffer (supplied in
kit) to which 4 mM NaCl, 1% Triton X-100, and 200µM PMSF are
added. Total protein is quantified by the Bradford assay and 25µg
total protein per well was assayed in triplicate. PARP activity was
measured in histone-coated strip wells using the High Through-
put (HT) Chemiluminescent PARP/Apoptosis Assay (Trevigen)
following the manufacturer’s procedures. This ELISA measures
the incorporation of biotinylated poly(ADP-ribose; PAR) into his-
tone proteins by chemiluminescence after samples are incubated
with anti-PAR antibody and then HRP-conjugated secondary anti-
body (anti-mouse IgG-HRP). Readings were taken using an HT
Analyst Criterion Host, and the light output was proportional
to PARP-1 activity. PARP activity for each sample is calculated
from a standard curve ran in triplicates within each experi-
ment. Results are expressed in mUnits PARP activity/µg of total
protein.
In vitro PARP-1 activity was measured HT Universal Chemi-
luminescent PARP Assay (Trevigen) following the manufacturer’s
instructions.
Inhibitors are identified when a PARP mediated increase in
fluorescence signal indicating the accumulation of NAD+ (or
the decrease in the PARP mediated depletion of NAD+). In the
absence of PARP maximal signal is observed, whereas in its pres-
ence minimal signal is observed and% inhibition is calculated:
% inhibition= 100 x [NAD remaining] for inhibitor at specific
concentration/[NAD remaining] no inhibitor.
Since DMSO inhibits inhibitors were tested by serial dilution
in water. Readings were taken automatically by the HT Analyst
Criterion Host.
siRNA SILENCING OF PARP1
siRNAs (smart pool) were obtained from Thermo Scientific
Dharmacon (Lafayette, CO, USA). siRNA was transfected using
the NHBE Nucleofector kit (Lonza, Walkersville, USA), pro-
gram W-001. siPARP1/2 (200 nM) or scrambled siRNA (200 nM)
was used per 10 cm plate of CFBE41o− cells overexpressing
∆F508 CFTR. Following nucleofection, cells plated in fibronectin-
coated 6-well plates in Opti-MEM overnight. The following
day the medium was replaced with EMEM supplemented with
1% penicillin/streptomycin, 1% glutamate, and 10% FBS. Cells
were lysed and total protein quantified by the Bradford assay.
Immunoblots were probed for CFTR and PARP1 to assess
trafficking and protein knockdown, respectively, as described
above.
EX VIVO ASSAYS OF ABT-888 ON CFTR-DEPENDENT CURRENT
Mice were genotyped by RT-PCR using tail DNA and used for
experiments between age 14–17 weeks (24–30 g). Homozygous
∆508 CFTR mice (Cftrtm1 Eur ; van Doorninck et al., 1995) and
wild type littermates controls were used in the ex vivo experi-
ments. For ex vivo experiments, the mucosa from the distal third
of the ileum was stripped of muscle and mounted in Ussing cham-
bers as described previously (Robert et al., 2008). Indomethacin
(10µM) was added to both sides to block prostaglandin synthesis
and 10µM amiloride was added apically to inhibit electrogenic
Na+ absorption. CFTR-dependent I sc was measured after 10–
15 min equilibration, then 10µM forskolin and 50µM genistein
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were added (0 h). Both sides were then exposed to 1 nM ABT-
888 or vehicle (distilled water) for 4 h, and the I sc response to
forskolin+ genistein was measured again. Results are expressed
as the mean± SEM of n pieces of ileum from 5 wt-CFTR and 5
∆F508 mice.
SALIVARY SECRETION
The procedure followed those described by Best and Quinton (Best
and Quinton, 2005). Homozygous ∆F508 CFTR mice (Cftrtm1
Eur ; French et al., 1997) and wild type littermates were used at
10–12 weeks, 20–25 g. They were injected intraperitoneally with
saline containing ABT-888 (5 mg/kg/day) or vehicle alone (saline)
for 2 days. Details of the procedure have been described (Robert
et al., 2008). Results are expressed as the mean± SEM of N mice.
RESULTS
ELEVATED PARP-1 ACTIVITY IN HUMAN CF BRONCHIAL EPITHELIAL
CELLS
We measured PARP-1 activity in CF and non-CF primary HBEs
by using ELISA to determine the rate at which its substrate
NAD+ is assembled into polymers of ADP-Ribose as illustrated
in Figure 1A. PARP-1 activity was 2.9-fold higher in HBEs from
two CF patients when compared with cells from two non-CF
subjects (Figure 1B, Students t -test, P < 0.05). Since primary
HBEs may vary due to differences in genetic background and per-
haps previous infection and inflammation history, PARP-1 activity
was also measured in the commonly used CF and non-CF cell
lines CFBE41o− and 16HBE14o−, respectively, which express only
endogenous mutant or wild type CFTR at low levels. PARP-1 activ-
ity was also higher in the CF cell line compared with the non-CF
line (Figure 1C, 2.5-fold, n= 6, Students’ t -test, P = 0.002), as
observed in primary HBEs. PARP-1 activity in CFBE41o− cells
was sensitive to ABT-888 (Veliparib) at 1 nM, decreasing PARP-1
activity ∼40% (P < 0.05), but not reducing it to wild type levels.
ABT-888 is a potent inhibitor of PARP-1 in other cells systems,
where it has an IC50= 5 nM (Donawho et al., 2007). We treated
wild type cells with ABT-888 (1 nM) and found that we could not
abolish PARP-1 activity (Figure 1C), in agreement with previous
evidence that some baseline PARP-1 activity is required for the
maintenance of genomic stability (Luo and Kraus, 2005).
FIGURE 1 | PARP activity is elevated in CF primary and transformed
epithelial cells and ABT-888 decreases PARP and activity in CF cells.
(A) (a) PARP-1 cleaves NAD+, releasing ADP-Ribose at the expense of
ATP (b) PARP-1 synthesizes polymers of ADP-Ribose onto acceptor
proteins (B) PARP-1 activity was measured in primary lung epithelial cells
from two CF patients and non-CF donors. Activity is reported as mUnits
of PARP-1/total protein (µg), where 1 unit is defined as the amount of
PARP-1 that incorporates 100 pmol poly (ADP-ribose) from NAD+ into an
acid-insoluble form. Bar graph shows the mean±SD from n=3
measurements per patient, and *denotes a significant difference at a
P <0.05 (two-tailed Student’s t -test). (C) PARP-1 activity is higher in the
CFBE41o− (CF) cell line than in the 16HBE14o− (non-CF) cell line. PARP-1
activity is reduced by ∼40% in CFBE cells upon treatment with the
PARP-1 inhibitor ABT-888 at the 1 nM (24 h) but ABT-888 has no effect on
PARP-1 activity in the non-CF 16HBE14o−. Bar graph represents the
mean±SEM from n=5 with three replicates each. Results are
considered significant at *P =0.0002 and **P <0.05, as assessed by
the paired, two-tailed Student’s t -test.
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MODULATING PARP-1 ACTIVITY RESTORES CHLORIDE FUNCTION
To examine the influence of PARP-1 on CFTR channel activity,
iodide (I−) efflux was measured from BHK cells overexpressing
∆F508 CFTR after pretreatment with PARP-1 inhibitors for 24 h.
Cells were pretreated with inhibitor, loaded by incubation in iodide
solution for 1 h, then stimulated acutely with 10µM forskolin
(Fsk) in combination with the potentiator 50µM genistein (Gst).
Pretreating cells with a well characterized corrector VRT325
(10µM, 24 h) increased the iodide efflux threefold compared
to the DMSO vehicle control (Figures 2A,B, P < 0.05, Student’s
t -test), consistent with a previous report (Loo et al., 2005). Pre-
treatment with ABT-888 increased iodide efflux (2.7-fold above
DMSO; Figure 2B, n= 3, Students’ t -test, P < 0.05) to levels com-
parable to VRT325. We also tested other PARP-1 inhibitors with
different structures (though all share the same carbonyl group),
potencies and mechanisms of action (see Figure 2C for structures),
and an inactive analog of 4-AN (4-ANin; Figures 2B,C). Both PJ34
and 4-AN increased forskolin+ genistein stimulated iodide release
from BHK cells stably expressing ∆F508 CFTR, suggesting par-
tial rescue of functional channels to the cell surface representing
FIGURE 2 | PARP-1 inhibitors partially restore chloride activity in (BHK)
CFTR ∆F508 and in polarized CFBE41o− (∆F508) cells. (A) Iodide efflux
trace measuring ∆F508 CFTR function at the plasma membrane in BHK cells
treated with ABT-888 (1 nM), DMSO (0.1%), and VRT325 (10µM) for 24 h.
Iodide efflux trace of BHK cells expressing wild type (wt) CFTR is also shown.
An arrowhead and bar graph indicate addition and maintenance, respectively,
of 10µM forskolin (Fsk) and 50µM genistein (Gst). Error bars indicate ±SD
(n=3). Note break in axis (B) change in iodide efflux upon stimulation with
Fsk and Gst defined as the peak iodide efflux after stimulation subtracted
from the baseline response summarizing data from all compounds tested;
4-AN (0.1µM), 4-ANin (0.1µM), PJ34 (10µM), ABT-888 (1µM). VRT-325
(10µM) and DMSO (0.1%). Error bars indicate ±SEM (n=3). A difference in
the means as compared with the DMSO control was tested for statistical
significance using paired t -tests (*P <0.05). (C) Chemical structures of the
PARP-1 inhibitors and the inactive 4-AN their published IC50 (PARP-1 inhibition)
are shown. The extent of PARP-1 inhibition (in vitro) was determined for each
of the compounds by measuring the NAD+ remaining in the presence of
inhibitor. Results are reported as %inhibition of PARP-1. VRT325, as expected
is not a PARP-1 inhibitor and 4-ANin, an inactive analog of 4-AN, is also not an
inhibitor. ABT-888 is the most potent PARP-1 inhibitor we tested. The graph
summarizes the data from three independent experiments representing the
mean±SEM. (D–G) Four panels show polarized CFBE41o− cells stably
overexpressing ∆F508 CFTR treated with DMSO (0.1%), ABT-888 (1 nM),
VRT325 (10µM), and low temperature incubation (29˚C) for 24 h and current
was measured in Ussing chamber. CFTR-mediated currents cause upward
deflections because an apical to basolateral current was imposed after
permeabilization of the basolateral membrane. (H) Bar graph showing the
change in Isc (disk) after the addition of 10µM Fsk and 50µM Gst, defined as
the difference between the sustained current after genistein and baseline
arrest before stimulation. Error bars represent mean±SEM (n=4) at
(*P <0.05), (**P <0.001), or (***P <0.0001) relative to DMSO (paired
t -tests). Note break in y -axis.
www.frontiersin.org September 2012 | Volume 3 | Article 165 | 5
Anjos et al. PARP1 inhibition corrects mutant CFTR
approximately half of the response obtained with VRT325. The
inactive analog (4-ANin) that does not inhibit PARP-1 had no
effect (Figure 2B). We monitored the in vitro PARP-1 activities of
the inhibitors tested and found that their relative ability to inhibit
PARP-1 correlated with their ability to restore iodide release in
(BHK) ∆F508 CFTR (graph, Figure 2C) suggesting that their
effects are mediated through the inhibition of PARP-1.
These experiments were extended to polarized CFBE41o− cells
that overexpress ∆F508 CFTR. Figures 2D–G shows short-circuit
current responses to forskolin and genistein and sensitivity to
the CFTR inhibitor (CFTRinh-172) after monolayers had been
incubated with 1 nM ABT-888 for 24 h. ABT-888 increased the
short-circuit current response to forskolin and genistein by almost
double compared to that of vehicle controls (Figures 2D,E). This
was approximately half the rescue elicited by VRT325 (Figure 2F),
and much less than that produced by low temperature pretreat-
ment (Figure 2G) as reported previously for other correctors
(Robert et al., 2010). The results under each condition are sum-
marized in Figure 2H. Thus, ABT-888 causes partial rescue of the
CFTR-dependent short-circuit current response, which is 6.7% of
that measured after low temperature incubation and 40% of that
induced by the well studied corrector VRT325.
DECREASING PARP-1 ACTIVITY IN VIVO RESTORES CHLORIDE ACTIVITY
To determine if PARP-1 inhibitors are effective in other tissues,
mouse ileum was mounted in Ussing chambers and treated ex
vivo with 1 nM ABT-888 for 4 h. Short-circuit current responses
to forskolin and genistein were measured using pieces of ileum
dissected from ∆F508 CFTR homozygotes and non-CF litter-
mate controls. These were first taken at time 0 (Figure 3A),
and then measured after 4 h incubation with 1 nM ABT-888
(Figure 3B) or saline alone (Figure 3B). Incubation with ABT-
888 for 4 h increased the response to forskolin+ genistein by
∼30% relative to that measured at time 0 (Figure 3C, N = 5,
Students’ t -test, P < 0.05). Incubation in saline alone for 4 h did
not alter the I sc response to forskolin+ genistein (Figure 3C).
The increase observed after this relatively brief (i.e., 4 h) expo-
sure to ABT-888 indicates restoration of ∼7% of the wild type
current response. PARP-1 activity in mouse ileum was mea-
sured by ELISA immediately after experiments with and without
ABT-888. Incubation with ABT-888 for 4 h inhibited 85% of the
PARP-1 activity measured in parallel experiments in control saline
(Figure 3D, n= 3, Student’s t -test, P < 0.05) confirming that it is
absorbed rapidly and is effective in native tissue (Muscal et al.,
2010).
FIGURE 3 | PARP inhibition partially restores the activity of mouse
∆F508 CFTR. (A-B) Representative short-circuit current (Isc) traces from
mouse ileum from ∆F508-CFTR homozygous mice and non-CF control
littermates. 10µM forskolin (Fsk) and 50µM genistein (Gsk) were added
before [(A), time 0 h] and after [(B), 4 h] incubation with 1 nM ABT-888.
(C) Bar graph showing the change in short-circuit current (∆Isc) after
adding Fsk+Gst. Isc responses were measured using 2–3 pieces of ileum
from each mouse before (0 h) and after (4 h) pre-treatment with vehicle
(N =5 mice), or ABT-888 (N =5 mice). Data are presented as the
mean±SEM; relative to their respective controls at time 0 h, calculated
using a paired t -test; *P < 0.05. Note break in axis. (D) PARP-1 activity in
vehicle-treated ileum (N =5 mice) and ABT-888 treated ileum (N =5 mice)
after 4 h incubation. Data are expressed as mean±SEM, and significance
was calculated by paired t -test; *P <0.05. (E) ABT-888 partially restores
salivary secretion in mouse salivary glands. Total saliva secreted by
homozygous ∆F508 CFTR mice after daily intraperitoneal injection with
vehicle (saline; n=5) or ABT-888 (n=5) for 2 days. Means±SEM;
*P <0.05 by a paired Student’s t -test.
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Studies were also carried out to assess in vivo correction in
∆F508 mice (van Doorninck et al., 1995). ABT-888 (5 mg/kg/day)
in saline was given daily by intraperitoneal injection; 3 mg/kg/day
dose has been shown previously to inhibit PAR activity in vivo
(Donawho et al., 2007) and results were compared with saline
alone. β-adrenergic stimulated salivary secretion was measured
by subcutaneous injection of isoprenaline into the cheek after
blocking cholinergic stimulation with atropine (Best and Quinton,
2005). ABT-888 injections increased the saliva secretion response
to isoprenaline 2.6 times when compared with untreated CF mice
(Figure 3E, P < 0.05). This corresponds to 7.8% of the response
of wild type mice (51.8± 2.4µg g−1 vs. 667.5± 4.2µg g−1;
Figure 3E).
PARP-1 INHIBITION PROMOTES∆F508 CFTR MATURATION
Since we observed an improvement in chloride channel activity
levels with PARP-1 inhibition, we assume that∆F508 had matured
beyond the ER. To examine this further we monitored the matura-
tion of∆F508 CFTR by immunoblotting CFBE41o− cells (overex-
pressing∆F508 CFTR) that had been treated with 1 nM ABT-888.
After 6 h we observed a band migrating at 175 kDa that may be
complex glycosylated ∆F508 CFTR (band C; see Figure 4A). We
also observed an increase in the core-glycosylated (band B) form
of ∆F508 CFTR (Figure 4A). We quantified the relative amounts
of each band by densitometry and found a significant increase
in the fraction of mature CFTR (band C/total) treated with
ABT-888 (0.34± 0.04) when compared with DMSO (0.20± 0.05),
Figure 4B (P = 0.02). We ruled out transcriptional effects of ABT-
888 by monitoring the relative abundance of CFTR mRNA at 6 and
24 h treatment with ABT-888. When CFBE41o− cells overexpress-
ing ∆F508 CFTR were treated with ABT-888 (1 nM), real-time
PCR revealed no change in CFTR mRNA levels after both 6
and 24 h exposure (Figure 4C, P = n.s). To test for specificity of
ABT-888, we monitored the maturation of wild type CFTR in
CFBE41o− cells (exogenously expressing wt-CFTR) treated with
ABT-888 and two other PARP-1 inhibitors, PJ34 and 4-AN by
immunoblotting (Figure 4D). However we found no effects on the
steady-state levels of the immature or mature glycoforms of wild
type CFTR, suggesting that PARP-1 inhibition targets the ∆F508
CFTR mutant specifically. The specificity of PARP-1 inhibition
was assessed by comparing the ability of ABT-888 and 4-AN to
correct the mutant form of the human ether-à-go-go-related K+
channel (hERG: hERG G601S) expressed in HEK 293 cells, which
is also retained in the ER (Figure 4E). PARP-1 inhibition did not
improve the processing of the mutant form of hERG (Figure 4E)
whereas VRT-325 increased the amount of processed hERG G601S
(Figure 4E). Artemizole and low temperature incubation (29˚C)
are known to correct G601S and are shown as positive controls
(Figure 4E). The different selectivities of VRT-325 and the PARP-1
inhibitors also suggest they act through distinct pathways.
To determine if the trafficking correction observed is indeed
PARP-1 dependent we examined the effect of silencing PARP-1 in
CFBE41o− cells that overexpress ∆F508 CFTR. siRNA-mediated
silencing of PARP-1 (which accounts for 85–90% of the pADPr
protein in mammalian cell; Pacher and Szabo, 2008) reduced
PARP-1 protein expression as expected (Figure 4F), and this was
accompanied by the appearance of some complex glycosylated
(band C)∆F508 CFTR, indicating escape from the ER (Figure 4F).
We quantified the relative amounts of band C and band B by den-
sitometry and found a significant increase in the mature form of
CFTR upon silencing of PARP-1 by siRNA (0.35± 0.04) relative
to si-scramble and/or untransfected (Figure 4G) when normal-
ized to tubulin. To extend this to a cell system that is devoid
of PARP-1, we carried out experiments with PARP-1−/− mouse
embryonic fibroblasts (MEFs) that had been transfected with
triple-HA tagged ∆508 CFTR (Figure 4H). ∆F508CFTR-3HA
was found almost exclusively in the complex glycosylated CFTR
(band C) form (Figure 4H) confirming that the effect of PARP-
1 inhibitors on the trafficking of ∆F508 is mediated by PARP-1
and is not an off-target drug effect. We quantified the relative
amounts of immature and mature forms of CFTR normalized
against tubulin in PARP-1−/− MEF cells (Figure 4I) and found
there was no significant difference in the amount of mature CFTR
in ∆F508 transfected PARP-1−/− MEFs vs. wCFTR transfected
cells (Figure 4I, P = n.s.). There was more immature CFTR (band
B) in the ∆F508 CFTR transfected cells even when corrected for
loading with tubulin (Figure 4I, ∗P < 0.05).
In MEF cells expressing PARP-1 (PARP-1+/+) the complex gly-
cosylated (band C) form of CFTR was only detected when wild
type CFTR was transfected, whereas ∆F508CFTR was found pre-
dominantly in the core-glycosylated (band B) form (Figures 4H,I)
as expected. Particularly striking is the increase in the expression
of CFTR in the absence of PARP-1−/− (Figure 4I, P < 0.05). We
calculated the ratio of band B/C (Figure 4J), which we expect to be
higher in the ∆F508 CFTR transfected PARP-1+/+ cells. While in
the PARP-1−/− transfected cells there is no difference between the
band B/C ratio in wCFTR and ∆F508 transfected cells (Figure 4J,
P = n.s.), in the PARP-1+/+ cells the band B/C ratio for ∆F508
transfections is five times higher (2.0± 0.7 for ∆F508 CFTR vs.
0.41± 0.14 for wCFTR, Figure 4J, P < 0.05).
INCREASING PARP-1 ACTIVATION WITH PEROXYNITRITE INHIBITS THE
TRAFFICKING OF WILD TYPE CFTR
Since reducing PARP-1 activity restores mutant CFTR trafficking
and function, we hypothesized that increasing PARP-1 activation
should reduce trafficking. To test this hypothesis and monitor traf-
ficking decreases, CFBE41o− cells expressing heterologous wild
type CFTR was exposed to the physiologically relevant PARP-
1 activator peroxynitrite (Szabo et al., 2007). PARP-1 activity
was increased by acute peroxynitrite treatment (3 h) with 100
and 250µM, reaching a maximal two-fold increase at 250µM
(Figure 5A). This inhibition was partially blocked by ABT-888,
confirming that the stimulation by peroxynitrite occurs through
the activation of PARP-1 (Figure 5A).
Treating CFBE41o− cells overexpressing wild type CFTR with
250µM peroxynitrite caused a marked reduction in complex
glycosylated CFTR (Figure 5B), Increasing PARP-1 activity also
increased the retention of core-glycosylated CFTR in the ER
(Figure 5B). There was also some reduction in total CFTR protein
expression at 100 and 250µM. This reduction was apparently not
due to apoptosis since cleavage of PARP-1 into 85 and 100 kDa
fragments, a hallmark of apoptosis, was not observed (Figure 5B).
We also observed increased PARP-1 expression in cells treated
with 100–250µM peroxynitrite (compared to untreated wild type
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FIGURE 4 | PARP-1 pharmacological inhibition and genetic deletion
promotes the trafficking of ∆F508 CFTR in CFBE41o− cells.
(A) CFBE41o− cells expressing ∆F508 CFTR were treated for the indicated
times with 1 nM ABT-888 and immunoblotted against CFTR to monitor
increases in complex glycosylation (band C). Note the appearance of band
C with ABT-888 treatment and an increase in band B. Band A is also
detected (ABT-888 and DMSO). (B) Mean±SD ratios of the densitometry
signals for band B/total and band C/total, normalized against tubulin.
*P <0.05 (n=3, t -test). (C) To rule out transcriptional up-regulation by
ABT-888, the relative expression of CFTR mRNA in CFBE41o− cells (not
overexpressing CFTR) was quantified by qRT-PCR. Although there is a
trend toward a decrease in CFTR mRNA with ABT-888 treatment at the
indicated times it does not reach statistical significance. Results are
reported as mean±SD, P = n.s (n=3, t -test). (D) PARP-1 inhibitors do not
increase the trafficking of wild type CFTR overexpressed in CFBE41o−
cells and (E) ABT-888 treated HEK 293 cells overexpressing the mutant
HERG (G601S) does not increase the trafficking of the ER-retained HERG
mutant G601S. We also tested 4-AN at the indicated concentrations in the
same system and found no effects suggesting specificity of ABT-888 for
the ∆F508-CFTR mutant. (F) PARP-1 silencing by siRNA partially restores
the trafficking of ∆F508 CFTR in CFBE41o− (overexpressing ∆F508) cells.
Immunoblot analysis of CFTR following siRNA-mediated silencing of
PARP-1 (48 h). PARP-1 knockdown was monitored by immunoblotting
against PARP-1; PARP-1 expression was significantly reduced compared to
si-scramble but was not completely abrogated. Note the appearance of
band C in siPARP-1 and an increase in band B. (G) Mean±SD ratios of the
densitometry signals for band B/total and band C/total, normalized against
tubulin. *P <0.05 (n= 3, t -test). (H) Complete deletion of PARP-1 restores
∆F508 trafficking. Mouse embryonic fibroblasts lacking PARP-1 (PARP1−/−)
were transfected with wild type CFTR or ∆F508 CFTR in pCDNA3.1 (and
empty plasmid, MOCK). The cells were lysed and analyzed by
immunoblotting with anti-CFTR (23C5, 1:20 dilution). Most detectable
CFTR migrates at 175 kDa, suggesting the complex glycosylated form of
∆F508 CFTR is predominant in cells lacking PARP-1. When MEF cells
containing PARP-1 (PARP1+/+) are transfected with same constructs the
level of CFTR expression was much lower overall no band C is detected in
∆F508. (I) Mean±SD ratios of the densitometry signals for band B/total
and band C/total, normalized against tubulin. *P < 0.05 (n= 3, t -test) (J)
band B/C ratios indicate more band B, as expected in the PARP-1+/+ cells
for ∆F508 CFTR, while in the PARP-1−/− cells there is no difference
between the wCFTR and ∆F508 CFTR transfections, suggesting that
most of the CFTR is in the mature band C form. *P <0.05 (n=3, t -test).
cells), which reached levels that were comparable to those in
CFBE41o− cells overexpressing ∆F508 CFTR (Figure 5B).
Overall, our data suggests interdependence between the levels
of oxidative stress, PARP activation and CFTR biogenesis. Taken
together, we have shown in several CF models, including human
primary bronchial epithelial cells (Figure 1B) and in CF cells (that
do not overexpress ∆F508, Figure 1C), that PARP-1 activity is
elevated when compared to matched non-CF cells. This suggests
oxidative stress caused by a misfolded protein, leading to increased
PARP-1 activity.
Decreasing the levels of PARP-1 activity by treatment with
PARP-1 inhibitors or the absence of PARP-1, results in a partial
restoration of ∆F508 CFTR trafficking and its function.
DISCUSSION
High PARP-1 activation in response to oxidant-mediated DNA
damage is an important pathway during tissue injury (Pacher
and Szabo, 2008). In this study we considered the modulation
of PARP-1 activity by pharmacological inhibition and genetic
silencing or deletion and how this affects CFTR function and
expression. Physiologically relevant levels of DNA damage and
PARP-1 activation have been demonstrated in pulmonary diseases,
such as asthma, acute lung injury, and COPD (42–45), however
these have not been investigated in CF. In view of the central role
it plays in cellular stress responses (Luo and Kraus, 2005) and
reports of exaggerated inflammation (Galli et al., 2012), elevated
oxidative stress (Galli et al., 2012), and metabolic dysregulation in
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FIGURE 5 | Increasing PARP-1 activity decreases trafficking of wild type
CFTR. (A) 16HBE14o− (non CF) were treated with the indicated doses of
peroxynitrite (ONOO−), a potent PARP-1 activator. PARP-1 activity was
monitored by ELISA. PARP-1 significantly increased at 250µM ONOO− (3 h
treatment). Blocking PARP-1 with ABT-888 abolished the effects of
peroxynitrite on PARP-1 activation suggesting that the effects we see are
PARP-1 mediated. Bar graph represents the mean±SEM (n= 3, with three
replicates each). Statistical significance was determined using a paired t -test;
*P <0.05. (B) To monitor trafficking decreases, CFBE41o− cells stably
overexpressing wild type (wt) treated with the indicated concentrations of
ONOO− for 3 h. Lysates from CFBE41o− cells overexpressing ∆F508 CFTR
are also shown. A decrease in trafficking promoted by ONOO− is observed at
250µM ONOO− with a decrease in complex glycosylated CFTR. No cleavage
of PARP-1 was observed.
CF patients (Wetmore et al., 2010), we hypothesized that PARP-1
might influence CFTR biology.
We observed higher PARP-1 activity in HBEs derived from
patients homozygous for ∆F508 CFTR than in HBEs from non-
CF donors, and similarly higher activity in the CFBE41o− cell
line compared to the non-CF line 16HBE14o−. To our knowl-
edge this is the first evidence that PARP-1 is upregulated in CF.
Although there may be many differences between the CFBE41o−
and 16HBE14o− cell lines, e.g., in the functional expression of
drug-transporter P-gp assayed by Rhodamine123 (Ehrhardt et al.,
2006), a major distinguishing feature is the presence of a mis-
folded and dysfunctional CFTR channel in CFBE41o−. Further
evidence that the difference in PARP-1 activity is due to the pres-
ence of ∆F508 CFTR comes from the results with primary cells
from patients. Despite the intrinsic variability between different
patients, the same pattern was observed, i.e., PARP-1 was higher
in cells from both CF patients compared to non-CF subjects. Nev-
ertheless, the relationship between CFTR and PARP-1 activity will
need to be extended to a larger cohort in the future.
Since PARP-1 is a DNA damage sensor, one might expect its
activity in CF cells to reflect increased DNA damage. Indeed,
DNA fragmentation has been reported in intestinal cells from CF
patients (Maiuri et al., 1997), and elevated levels of oxidative stress
markers and DNA damage have also been reported in CF (Brown
et al., 1995, 1996). CF patients present with several abnormalities
in oxidative stress, including elevated ROS generation, a consti-
tutive defect in glutathione metabolism, and reduced intake of
fat-soluble antioxidant vitamins (Galli et al., 2012), some of which
are endogenous or natural PARP-1 inhibitors (Banasik et al., 1992).
Aside from nicotinamide, natural occurring inhibitors of PARP-
1 include tryptophan-related compounds, purines, unsaturated
fatty-acids (including linoleic acid and arachidonic acid), and
carotenoids (Banasik et al., 1992) the levels of which are reportedly
low in CF patients (Wetmore et al., 2010, Galli et al., 2012).
We observed a correlation between PARP-1 activity and CFTR,
consistent with reports that (1) CFTR dysfunction itself can lead
to oxidative stress (Bartoszewski et al., 2008; Chen et al., 2008),
(2) ROS reduce wild type CFTR protein expression and cAMP-
mediated Cl− secretion in airway epithelia (Bebok et al., 2002),
and (3) ER retention of CFTR may contribute to inflammation
(Rottner et al., 2009).
PARP-1 activity was modulated by treating CF epithelial cells
with the potent PARP-1 inhibitor ABT-888 (Veliparib) at low con-
centrations, lower than needed to observe maximal inhibition
of PARP-1 (maximum inhibition at 1 nM vs. IC50= 5 nM). The
reason for this extraordinary potency remains unknown, how-
ever it was observed in several cell types (Figures 1–3). ABT-888
inhibition of PARP-1 activity was variable among different cell
types, consistent with previous reports (Virag, 2005). For exam-
ple, inhibition was stronger in mouse ileum (Figure 3D). Although
ABT-888’s potency as a ∆F508 corrector has been evaluated in
recombinant cell lines and model systems it will be important to
investigate its action further in primary cells. Based on the previous
reports of correctors that work modestly in vitro (Pedemonte et al.,
2010) not advancing further into pre-clinical or human CF trials
for lack of specificity, off-target effects and/or insufficient levels of
restoration of trafficking (Pedemonte et al., 2010) highlights the
importance of assessing correctability in primary cells. We mea-
sured the effects of ABT-888 treatment on ∆F508 CFTR function
in native HBEs derived from a single patient by Ussing chamber
measurements of chloride activity and while we found a modest
increase in activity, this was not statistically significant (data not
shown). However, there is a reported large variation in the “cor-
rectability” by a single compound in different patients (the short
current response of CF primary lung bronchial epithelial cells to
VX-809 varied between 3.4–14.9% of non-CF donor lungs; Van
Goor et al., 2011). More patients will need to be tested. Addi-
tionally, we also predict that there will be variability in the levels
of oxidative burden and consequently PARP-1 activation between
patients. A larger cohort will have to be tested to address this.
Finally, peroxynitrite activated PARP-1 and reduced the mat-
uration of wild type CFTR (Figures 5A,B), and this effect was
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blocked by ABT-888, strongly suggesting that peroxynitrite was
acting through PARP-1. Although the activation of PARP-1 by
peroxynitrite and its involvement in disease is well documented
(Pacher and Szabo, 2008), peroxynitrite is a potent oxidant and we
cannot exclude other potential mechanisms of action (Figure 5A).
Previous studies have demonstrated that (1) oxidants affect CFTR
function (Rottner et al., 2009), (2) CFTR dysfunction itself may
lead to oxidative stress (Chen et al., 2008), (3) oxidative stress sup-
presses CFTR expression (Cantin et al., 2006; Bartoszewski et al.,
2011), and (4) increases in reactive oxygen nitrogen species may
decrease wild type CFTR protein expression and cAMP-mediated
Cl− secretion by airway epithelia (Bebok et al., 2002).
∆F508 CFTR maturation was dramatically altered in PARP-1
knockout cells. Only the mature glycoform was detected in PARP-1
null MEFs (Figure 4H). This is consistent with the partial restora-
tion of ∆F508 trafficking in CFBE41o− cells (Figures 4A,B) when
PARP-1 activity was inhibited pharmacologically or silenced by
RNA interference (Figures 4F,G). It has been shown that PARP-1
knockout mice display altered expression of redox-sensitive, AP-
1-dependent genes, proinflammatory mediators, and heat shock
proteins (including HSP70; Andreone et al., 2003) known to reg-
ulate CFTR gene expression, folding or function (McCarthy and
Harris, 2005). Moreover, the PARP-1 knockout mouse is also resis-
tant to various models of inflammation, the mechanism of which
occurs via deficient NF-κB activation (Schreiber et al., 2006),
which requires PARP-1 as a co-activator.
The effects of PARP-1 inhibition seem to be specific for the
mutant CFTR form, as we do not observe any improvements in
the processing of the wild type CFTR (Figure 4D) nor for the
mutant form of the human ether-à-go-go-related K+ channel
(hERG: hERG G601S) expressed in HEK 293 cells, which is also
retained in the ER (Figure 4E).
These results suggest that the effects we observe are ∆F508
CFTR specific and are linked to elevated oxidative stress, which
is not elevated in the wild type CFTR cells. We propose that
restoring homeostasis through the attenuation of PARP-1 activ-
ity increases translation and proteostasis at least partly because
oxidative stress is lowered. Although the mechanism of action is yet
undetermined, we hypothesize that PARy(lation) of key members
of the CFTR folding interactome such as the HSP90 co-chaperone
Hop, among others (Gagne et al., 2008), may alter their expression
and function promoting folding, and altering interactions with
partners, consistent with a rapid response (Figure 4A). PARP-1’s
role in intracellular trafficking is expanding as recently reviewed
(Abd Elmageed et al., 2011) highlighting the multiple roles and
pleiotropic effects of PARP related pathways.
Achieving therapeutically-relevant trafficking of ∆F508 CFTR
in vivo may require a combination of two or more corrector drugs,
and may also require antioxidant therapies due to underlying
defects in the regulation of oxidative stress and inflammation. The
present results suggest that addressing the trafficking and oxida-
tive stress problem through manipulation of PARP-1 and related
pathways may be a useful approach for restoring homeostasis and
should be investigated further in the context of CF therapeutics.
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